Jagsonpal Pharmaceuticals Ltd - 507789 - Submission Of The Outcome Of The Board Meeting.
Submission of the outcome of the Board Meeting.25-05-2021
25-05-2021
Jagsonpal Pharmaceuticals Ltd - 507789 - Board Meeting Intimation for Investment In The Associate Company Along With Other Routine Matters.
JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2021 ,inter alia, to consider and approve investment in the associate company along with other routine matters.14-05-2021
Jagsonpal Pharmaceuticals Ltd - 507789 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayJAGSONPAL PHARMACEUTICALS LTD. 2CINL74899DL1978PLC009181 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 6.75 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: NANDITA SINGH Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: csnanditasingh@gmail.com Name of the Chief Financial Officer: SANJIV KUMAR DUDEJA Designation: CHIEF FINANCIAL OFFICER EmailId: sagar@jagsonpal.com Date: 28/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.28-04-2021
Jagsonpal Pharmaceuticals Ltd - 507789 - Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 201528-04-2021
Jagsonpal Pharmaceuticals Ltd - 507789 - Clarification For Price Movement.
Clarification for price movement.27-04-2021
Jagsonpal Pharmaceuticals Ltd - 507789 - Clarification sought from Jagsonpal Pharmaceuticals Ltd
The Exchange has sought clarification from Jagsonpal Pharmaceuticals Ltd on April 26, 2021 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.26-04-2021
Jagsonpal Pharmaceuticals Ltd - 507789 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In Compliance with Regulation 74 (5) of SEBl (Depositories and Participants) Regulations, 2018 we are forwarding herewith a copy of the Certificate received from M/s MCS Share Transfer Agent Limited, the Registrar and Share Transfer Agent of the Company, for the quarter ended 31st March, 2021. This is for your information & record.22-04-2021
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliance Certificate Pursuant To Regulations 7(3) Of The SEBI (LODR) Regulations, 2015 For The Half Year Ended 31 March, 2021.
Compliance Certificate pursuant to regulations 7(3) of the SEBI (LODR) Regulations, 2015 for the half year ended 31 March, 2021.22-04-2021
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Shareholding for the Period Ended March 31, 2021
Jagsonpal Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here19-04-2021
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- NANDITA SINGHDesignation :- Company Secretary and Compliance Officer14-04-2021